Neuren Pharmaceuticals Limited (NURPF)
USD 8.22
(0.0%)
USD 8.22
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 184.92 Million | 3.59 Million | -9.97 Million | -8.07 Million | -11.71 Million | 6.4 Million |
| Net Income | 157.08 Million | 184 Thousand | -7.79 Million | -9.19 Million | -10.81 Million | 3.07 Million |
| Depreciation & Amortization | 17 Thousand | 10 Thousand | 8000.00 | 6000.00 | 4000.00 | 77 Thousand |
| Deferred income taxes | -2.92 Million | -1.98 Million | -840 Thousand | -394 Thousand | - | - |
| Stock-based compensation | 2.92 Million | 1.98 Million | 840 Thousand | 394 Thousand | - | - |
| Change in working capital | 23.23 Million | 533 Thousand | -2.62 Million | -9000.00 | -1.02 Million | 143 Thousand |
| Other non-cash items | 4.59 Million | 2.87 Million | 436 Thousand | 1.11 Million | 117 Thousand | 3.12 Million |
| Investing Cash Flow | -211.48 Million | -19 Thousand | -10 Thousand | -6000.00 | -12 Thousand | - |
| Investments in PPE | -40 Thousand | -19 Thousand | -10 Thousand | -6000.00 | -12 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -211.44 Million | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -211.44 Million | - | - | - | - | - |
| Financing Cash Flow | 3.61 Million | -2000.00 | 22.17 Million | 19.14 Million | 1.86 Million | 11.71 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -18 Thousand | -2000.00 | -1.1 Million | -1.07 Million | - | -16 Thousand |
| Common Stock Issuance | 3.61 Million | -2000.00 | 23.28 Million | 20.21 Million | 1.86 Million | 11.73 Million |
| Other Financing Activities | 18 Thousand | -2000.00 | 22.17 Million | 19.14 Million | 1.86 Million | 11.71 Million |
| Accounts receivables | -15.55 Million | 194 Thousand | -2.5 Million | -203 Thousand | 390 Thousand | -250 Thousand |
| Accounts payables | 2.44 Million | 339 Thousand | -114 Thousand | 194 Thousand | -1.41 Million | 393 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 36.34 Million | - | - | - | - | - |
| Cash at beginning of period | 40.18 Million | 36.78 Million | 24.18 Million | 13.84 Million | 23.57 Million | 4.7 Million |
| Cash at end of period | 17.09 Million | 40.18 Million | 36.78 Million | 24.18 Million | 13.84 Million | 23.57 Million |
| Capital Expenditure | -40 Thousand | -19 Thousand | -10 Thousand | -6000.00 | -12 Thousand | - |
| Effect of forex changes on cash | -145 Thousand | -181 Thousand | 400 Thousand | -713 Thousand | 141 Thousand | 748 Thousand |
| Net cash flow / Change in cash | -23.08 Million | 3.39 Million | 12.59 Million | 10.34 Million | -9.73 Million | 18.87 Million |
| Free Cash Flow | 184.88 Million | 3.58 Million | -9.98 Million | -8.08 Million | -11.73 Million | 6.4 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 4 Million | 4 Million | 157.08 Million | 109.27 Million | 54.63 Million | 47.8 Million |
| Depreciation & Amortization | 5500.00 | 5500.00 | 17 Thousand | 11 Thousand | 5500.00 | 6000.00 |
| Deferred income taxes | - | - | -2.92 Million | -968.5 Thousand | - | -529.49 Thousand |
| Stock-based compensation | 382.5 Thousand | 382.5 Thousand | 2.92 Million | 946.5 Thousand | 946.5 Thousand | 517.49 Thousand |
| Change in working capital | 1.87 Million | 1.87 Million | 23.23 Million | 26.82 Million | -5.98 Million | -3.58 Million |
| Other non-cash items | -16.53 Million | -16.53 Million | 4.59 Million | 3.95 Million | 20.41 Million | 666 Thousand |
| Investing Cash Flow | 420 Thousand | 420 Thousand | -211.48 Million | -211.46 Million | -105.73 Million | -18 Thousand |
| Investments in PPE | -1500.00 | -1500.00 | -40 Thousand | -22 Thousand | -11 Thousand | -18 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -211.44 Million | -211.44 Million | - | - |
| Sales/Maturities of investments | 843 Thousand | - | - | - | - | - |
| Other Investing Activities | 421.5 Thousand | 421.5 Thousand | -211.44 Million | -105.72 Million | -105.72 Million | - |
| Financing Cash Flow | 825.5 Thousand | 825.5 Thousand | 3.61 Million | 2.52 Million | 1.26 Million | 1.09 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -18 Thousand | - | - | - |
| Common Stock Issuance | 1.65 Million | - | 3.61 Million | 2.52 Million | - | 1.09 Million |
| Other Financing Activities | 825.5 Thousand | 825.5 Thousand | 18 Thousand | 1.26 Million | 1.26 Million | 548.5 Thousand |
| Accounts receivables | 1.87 Million | 1.87 Million | -15.55 Million | -7.77 Million | -7.77 Million | - |
| Accounts payables | 1.05 Million | - | 2.44 Million | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -32.23 Million | - | 36.34 Million | 1.79 Million | 1.79 Million | -1.79 Million |
| Cash at beginning of period | 17.09 Million | - | 40.18 Million | 38.38 Million | - | 40.18 Million |
| Cash at end of period | 2.57 Million | -7.26 Million | 17.09 Million | 17.09 Million | -34.29 Million | 38.38 Million |
| Capital Expenditure | -1500.00 | -1500.00 | -40 Thousand | -22 Thousand | -11 Thousand | -18 Thousand |
| Effect of forex changes on cash | 1.76 Million | 1.76 Million | -145 Thousand | 158.5 Thousand | 158.5 Thousand | -231 Thousand |
| Net cash flow / Change in cash | -14.52 Million | -7.26 Million | -23.08 Million | -21.29 Million | -34.29 Million | -1.79 Million |
| Free Cash Flow | -10.26 Million | -10.26 Million | 184.88 Million | 140.02 Million | 70.01 Million | 44.86 Million |
3664
6144
4196
3276
5364
RKT